


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) Compounds of the general formula (I):




their enantiomers, diastereomers, racemates and mixtures thereof, in which:

(a) $[[R1]]$ R₁ may be


(1) a linear or branched alkyl radical, saturated or with from 1 to 6 double bonds, a monocyclic or polycyclic alkyl or alkenyl radical, or an aryl, arylalkyl or heterocyclic radical having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkylidithio or arylidithio, $-N^+[[R7R8R9]]R_7R_8R_9Z^-$ in which ~~R7, R8 and R9~~ R₇, R₈ and R₉ are identical to one another or different and may be alkyl, alkenyl or arylalkyl radical, and Z⁻ is the anion of a pharmaceutically acceptable organic or inorganic acid;

(2) a group of formula (II):



in which $[[R_4]]$ R_4 is a linear or branched alkylene radical saturated or with from 1 to 6 double bonds, a cycloalkylene or cycloalkenylene radical, or an aryl, arylalkyl or heterocyclic diradical with one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, acylamide, keto, nitro, alkoxy, halogen, mercapto, alkylthio, alkylidithio, or arylidithio, R_5 and R_6 have the meanings given below for R_2 and R_3 , respectively, or $[[R_5]]$ R_5 is a group of formula $-Y-OH$, where Y has the meaning described below in point (c);


(3) a group of formula (III):



in which $[[R_4]]$ R_4 has the meanings described above and $[[R_{10}]]$ R_{10} is hydrogen or a linear or branched alkyl radical or an arylalkyl radical, in which, when $[[R_{10}]]$ R_{10} is hydrogen, the resulting carboxylic group may optionally be salified with an organic or inorganic base to form a pharmaceutically acceptable salt;

(b) $[[R_2]]$ R_2 is selected from hydrogen or an alkyl, alkenyl or arylalkyl radical;

(c) $[[R3]]$ R_3 is a group of formula (IV):




in which:

Y is a linear or branched ~~alkylene~~ alkyl radical, optionally substituted with one or more phenyl groups, possibly substituted with one or ~~more~~ more hydroxy and/or alkoxy groups;

X is selected from:

(1) the radical or a cycloalkyl-ether ~~or cycloalkylthioether~~ with a ring of from 3 to 7 members, possibly substituted and possibly comprising a ~~second~~ one or two heteroatom;


(2) a group of formula (V):



in which $[[R11]]$ R_{11} is selected from: a linear or branched alkyl or alkenyl radical, possibly containing from 1 to 5 heteroatoms, which may be identical to one another or different, a monocyclic or polycyclic alkyl radical, an arylalkyl radical, an aryl radical or a heterocyclic radical which is aromatic or completely or partially saturated, having one or more heteroatoms, the radicals optionally being substituted with one or more groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, halogen,

-O-PO₃H₂, -O-PO₂H₂, -O-SO₃H, -SO₃H, ~~mercapto, alkylthio, alkylidithio, arylidithio,~~
 azido, -NH[[R₉]]R₉, -N[[R₇R₈]]R₇R₈, -N⁺[[R₇R₈R₉]]R₇R₈R₉ Z⁻, in which Z⁻ is the
 anion of a pharmaceutically acceptable organic or inorganic acid and ~~R₇, R₈ and R₉~~ R₇,
R₈ and R₉ are as defined above or ~~R₇ and R₈~~ R₇ and R₈ may form, together with the
 nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly
 containing other heteroatoms selected from oxygen, ~~sulphur~~ and nitrogen, the nitrogen
 possibly being substituted by an alkyl, benzyl or hydroxyethyl radical, and in which the
 basic and acid groups present in the molecule may possibly be salified with organic or
 inorganic acids and bases, respectively, to form pharmaceutically acceptable salts;

(3) a group of formula (VI):




in which:

(i) [[R₁₂]] R₁₂ is selected from: a linear or branched alkyl or alkenyl radical possibly
 containing from 1 to 5 heteroatoms which may be identical to one another or different, a
 mono- or polycyclic alkyl radical, an arylalkyl radical, an aryl radical or a heterocyclic
 radical which is aromatic or completely or partially saturated, having one or more
 heteroatoms, the radicals ~~optionally~~ optionally being substituted with one or more
 groups selected from hydroxy, amino, acylamino, keto, ureide, guanidino, nitro, alkoxy, -
 O-C₆H₄-W, halogen, -O-PO₃H₂, O-PO₂H₂, ~~-O-SO₃H, -SO₃H, mercapto, alkylthio,~~
~~alkylidithio, arylidithio,~~ azido, -NH[[R₉]]R₉, -N[[R₇R₈]]R₇R₈, -N⁺[[R₇R₈R₉]]R₇R₈R₉ Z⁻,
 in which Z⁻ is the anion of a pharmaceutically acceptable organic or inorganic acid, and

~~R7, R8 and R9~~ R₇, R₈ and R₉ are as defined above or ~~R7 and R8~~ R₇ and R₈ may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members, possibly containing other heteroatoms selected from oxygen, sulphur and nitrogen, possibly substituted with an alkyl, benzyl or hydroxyethyl radical, in which W is selected from hydrogen, alkyl, alkoxy, nitro, halogen, and hydroxy, and in which the basic and acid groups present in the molecule may possibly be salified with organic or inorganic acids and bases, respectively, to form pharmaceutically acceptable salts;


R₁₃ has, independently, the meanings of [[R₁₂]] R₁₂, or may be hydrogen;

(4) a group of formula (VII):



in which [[R₁₄]] R₁₄ is selected from: a linear or branched alkylene or arylalkylene radical, possibly substituted with a hydroxy group or [[-O-CO-R₁₅]] -O-CO-R₁₅, in which [[R₁₅]] R₁₅ is an alkyl, alkenyl or arylalkyl radical, ~~R7, R8 and R9~~ R₇, R₈ and R₉ are as defined above, or ~~R7 and R8~~ R₇ and R₈ may form, together with the nitrogen atom to which they are bound, a ring of from 3 to 7 members as defined above, and Z⁻ is a pharmaceutically ~~acceptable~~ acceptable inorganic or organic anion;

(5) a group of formula (VIII):



in which the $-\text{SO}_3^-$ group may be in the ortho, meta or para position relative to the keto group, and M^+ is a pharmaceutically acceptable inorganic or organic cation.

2. (currently amended) A compound according to Claim 1, ~~wherein~~ wherein ~~R₂ and R₅~~ R₂ and R₅ are identical to one another.
3. (currently amended) A compound according to Claim 1, wherein ~~R₃ and R₆~~ R₃ and R₆ are identical to one another.
4. (currently amended) A compound according to Claim 1, wherein ~~[[R₁]]~~ R₁ is a saturated or mono-unsaturated alkyl~~[[o]]~~ radical with from 1 to 23 carbon atoms.
5. (currently amended) A compound according to Claim 1, wherein ~~[[R₄]]~~ R₄ is a saturated or mono-unsaturated alkylene radical with from 1 to 20 carbon atoms.
6. (currently amended) A compound according to Claim 1, wherein ~~R₇, R₈ and R₉~~ R₇, R₈ and R₉ are alkyl or alkenyl radicals with from 1 to 7 carbon atoms.
7. (currently amended) A compound according to Claim 1, wherein ~~[[R₁₀]]~~ R₁₀ is an alkyl radical with from 1 to 20 carbon atoms.
8. (currently amended) A compound according to Claim 1, wherein ~~[[R₂]]~~ R₂ is an alkyl or alkenyl group with from 1 to 7 carbon atoms.

9. (previously presented) A compound according to Claim 1, wherein Y is an alkylene radical with from 2 to 20 carbon atoms.
10. (withdrawn)
11. (currently amended) A compound according to Claim 1, wherein ~~R11 or R12~~ R₁₁ or R₁₂ is an alkyl or alkenyl radical with from 1 to 25 carbon atoms.
12. (currently amended) A compound according to Claim 1, wherein ~~R7 and R8~~ R₇ and R₈ form, together with the nitrogen atoms to which they are bound, a ring having from 5 to 7 members.
13. (withdrawn)
14. (currently amended) A compound according to Claim 1, wherein ~~[[R14]]~~ R₁₄ is an alkylene radical with from 1 to 10 carbon atoms.
15. (currently amended) A compound according to Claim 1, ~~wherein~~ wherein ~~[[R15]]~~ R₁₅ is an alkyl or alkenyl radical with from 1 to 7 carbon atoms.
16. (currently amended) A medicament ~~emcompassing~~ comprising the compound according to Claim 1.
17. (currently amended) A drug with agonist activity in relation to a CB2 cannabinoid receptor comprising the ~~compound~~ compound according to Claim 16.

18. (currently amended) A ~~compound according to claim 1~~ method for the treatment of treating inflammatory processes or inflammatory processes with a hyperalgie component, each process having a neurogenic basis or an immunogenic basis, each basis being associated with a immuno-inflammatory condition, a ~~neurodegenerative~~ neurodegenerative pathological condition, or a pathological condition in which an non-psychomimetic effect of cannabinoids mediated either by CB2 receptors or by peripheral CB1 receptors ~~is noted~~, comprising administering a pharmaceutically effective amount of a compound of Claim 1.

19. (currently amended) A cosmetic additive comprising the compound ~~according~~ according to Claim 1.

20. (currently amended) A compound according to Claim 4, wherein ~~[[R1]]~~ R₁ is a saturated or mono-unsaturated alkyl radical with from 13 to 15 carbon atoms.

21. (currently amended) A compound according to Claim 5, ~~wherein~~ wherein ~~[[R4]]~~ R₄ is a saturated or mono-unsaturated alkylene radical with from 6 to 14 carbon atoms.

22. (currently amended) A compound according to Claim 6, wherein ~~R7, R8 and R9~~ R₇, R₈ and R₉ are methyl groups.

23. (previously presented) A compound according to Claim 9, wherein Y is an alkylene radical with 2 to 6 carbon atoms.

24. (withdrawn)

25. (currently amended) A compound according to Claim 11, ~~wherein~~ wherein ~~R₁₁ or R₁₂~~ R₁₁ or R₁₂ contains from 1 to 5 heteroatoms selected from the group consisting of: sulphur, oxygen and nitrogen.
26. (previously presented) A compound according to Claim 12, wherein the ring contains a further nitrogen atom that is non-substituted or is substituted by a methyl or ethyl group.
27. (currently amended) A compound according to Claim 14, wherein ~~[[R₁₄]]~~ R₁₄ is an alkylene radical with from 2 to 4 carbon atoms.